Defining the role of insulin detemir in Basal insulin therapy (Q37011970)

17 August 2017

1 reference

title

Defining the role of insulin detemir in Basal insulin therapy (English)

1 reference

17 August 2017

1 reference

1 reference

Javier Morales

1

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

67

1 reference

17 August 2017

17

1 reference

17 August 2017

2557-2584

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00007

17 August 2017

0 references

cites work

Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures

1 reference

12 December 2020

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

12 December 2020

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

1 reference

12 December 2020

Is continued weight gain inevitable in type 2 diabetes mellitus?

1 reference

12 December 2020

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

12 December 2020

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

12 December 2020

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

12 December 2020

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Tissue selectivity of insulin detemir action in vivo.

1 reference

12 December 2020

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus

1 reference

12 December 2020

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

12 December 2020

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

12 December 2020

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mell

1 reference

12 December 2020

Insulin analogues in the management of diabetes.

1 reference

12 December 2020

Variability of insulin absorption and insulin action

1 reference

12 December 2020

At last, a weight neutral insulin?

1 reference

12 December 2020

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

1 reference

12 December 2020

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

12 December 2020

Before oral agents fail: the case for starting insulin early

1 reference

12 December 2020

An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK

1 reference

12 December 2020

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

1 reference

12 December 2020

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

1 reference

12 December 2020

Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue

1 reference

12 December 2020

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

1 reference

12 December 2020

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes

1 reference

12 December 2020

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

12 December 2020

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

1 reference

12 December 2020

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

1 reference

12 December 2020

The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study

1 reference

12 December 2020

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

1 reference

12 December 2020

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

12 December 2020

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

1 reference

12 December 2020

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

1 reference

12 December 2020

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Insulin delivery using pen devices. Simple-to-use tools may help young and old alike

1 reference

12 December 2020

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

12 December 2020

Insulin detemir: from concept to clinical experience

1 reference

12 December 2020

Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes

1 reference

12 December 2020

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

12 December 2020

Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects

1 reference

12 December 2020

1 reference

12 December 2020

How to achieve a predictable basal insulin?

1 reference

12 December 2020

Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review

1 reference

12 December 2020

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

1 reference

12 December 2020

Reproducibility and variability in the action of injected insulin

1 reference

12 December 2020

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

12 December 2020

Safety and side effects of the insulin analogues

1 reference

12 December 2020

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

New insulins in the treatment of diabetes mellitus

1 reference

12 December 2020

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

12 December 2020

Can we reduce hypoglycaemia with insulin detemir?

1 reference

12 December 2020

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

12 December 2020

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

12 December 2020

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

1 reference

12 December 2020

Monomeric insulins obtained by protein engineering and their medical implications

1 reference

12 December 2020

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

1 reference

12 December 2020

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

12 December 2020

1 reference

12 December 2020

Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

1 reference

12 December 2020

Hypoglycemia in diabetes.

1 reference

12 December 2020

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

12 December 2020

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

1 reference

12 December 2020

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

12 December 2020

Subcutaneous insulin: pharmacokinetic variability and glycemic variability

1 reference

12 December 2020

10.2165/00003495-200767170-00007

Identifiers

DOI

1 reference

PubMed ID

18034591

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

18034591